Increased markers of inflammation and endothelial dysfunction in patients with mild primary hyperparathyroidism

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 71, Issue 2, 2011, Pages 139-144

  Almqvist, Erik G ^a   Bondeson, Anne Greth ^b   Bondeson, Lennart ^c   Svensson, Johan ^a  

^a CENTRAL HOSPITAL   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c Lund University   (Sweden)

Author keywords

and vascular cell adhesion molecule 1; C reactive protein; E selectin; interleukin 6; NT proBNP

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALCIUM; CREATININE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERLEUKIN 6; PARATHYROID HORMONE; PERTECHNETIC ACID TC 99M; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CONVALESCENCE; CORRELATION ANALYSIS; CREATININE CLEARANCE; DISEASE SEVERITY; ENDOTHELIAL DYSFUNCTION; ERYTHROCYTE SEDIMENTATION RATE; EXERCISE; FEMALE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INFLAMMATION; MALE; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROIDECTOMY; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCINTIANGIOGRAPHY;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; ENDOTHELIUM; FEMALE; HEART FUNCTION TESTS; HUMANS; HYPERPARATHYROIDISM, PRIMARY; INFLAMMATION; LINEAR MODELS; MALE; MIDDLE AGED; PARATHYROIDECTOMY;

EID: 79952376334     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.3109/00365513.2010.543694     Document Type: Article

References (23)

1. Andersson P, Rydberg E, Willenheimer R. Primary hyper-parathyroidism and heart Disease-a review. Eur Heart J 2004;25:1776-87. (Pubitemid 39330228)
2. Almqvist EG, Bondeson AG, Bondeson L, Nissborg A, Smedgård P, Svensson SE. Cardiac dysfunction in mild pri-mary hyperparathyroidism assessed by radionuclide angiog-raphy and echocardiography before and after parathyroidectomy Surgery 2002;132:1126-32. (Pubitemid 36026965)
3. Almqvist EG, Becker C, Bondeson AG, Bondeson L, Svensson J, Svensson SE. Increased plasma concentrations of N-terminal pro-B-type natriuretic peptide in patients with mild primary hyperparathyroidism. Clin Endocrinol (Oxf) 2006;65:760-6. (Pubitemid 44772356)
4. Devaraj S, Singh U, Jialal I. The evolving role of C-reactive protein in atherothrombosis. Clin Chem 2009;55:229-38.
5. Abeywardena MY, Leifert WR, Warnes KE, Varghese JN, Head RJ. Cardiovascular biology of interleukin-6. Curr Pharm Des 2009;15:1809-21.
6. Sprague AH, Khalil RA. Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem Pharmacol 2009; 78:539-52.
7. Roldán V, Marín F, Lip GY, Blann AD. Soluble E-selectin in cardiovascular disease and its risk factors. A review of the literature. Thromb Haemost 2003;90:1007-20. (Pubitemid 38004418)
8. Grey A, Mitnick MA, Shapses S, Ellison A, Gundberg C, Insogna K. Circulating levels of interleukin-6 and tumor necrosis factor-alpha are elevated in primary hyperparathy-roidism and correlate with markers of bone resorption-a clinical research center study. J Clin Endocrinol Metab 1996;81:3450-4. (Pubitemid 26339897)
9. Halabe A, Shohat B. Effect of parathyroid adenoma excision on interleukin-6 (IL-6) and IL-2 receptor levels. Metabolism 2000;49:192-4. (Pubitemid 30090882)
10. Guo CY, Holland PA, Jackson BF, Hannon RA, Rogers A, Harrison BJ, Eastell R. Immediate changes in biochemical markers of bone turnover and circulating interleukin-6 after parathyroidectomy for primary hyperparathyroidism. Eur J Endocrinol 2000;142:451-9. (Pubitemid 30341175)
11. Ogard CG, Engelmann MD, Kistorp C, Nielsen SL, Vestergaard H. Increased plasma N-terminal pro-B-type natriuretic peptide and markers of inflammation related to atherosclerosis in patients with primary hyperparathy-roidism. Clin Endocrinol (Oxf) 2005;63:493-8. (Pubitemid 41626742)
12. Chertok-Shacham E, Ishay A, Lavi I, Luboshitzky R. Bio-markers of hypercoagulability and inflammation in primary hyperparathyroidism. Med Sci Monit 2008;14:CR628-32.
13. Luboshitzky R, Chertok-Schaham Y, Lavi I, Ishay A. Car-diovascular risk factors in primary hyperparathyroidism. J Endocrinol Invest 2009;32:317-21.
14. Nakchbandi IA, Mitnick MA, Lang R, Gundberg C, Kinder B, Insogna K. Circulating levels of interleukin-6 soluble receptor predict rates of bone loss in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 2002;87: 4946-51. (Pubitemid 35316330)
15. Safley SA, Villinger F, Jackson EH, Tucker-Burden C, Cohen C, Weber CJ. Interleukin-6 production and secretion by human parathyroids. Clin Exp Immunol 2004;136:145-56. (Pubitemid 38437777)
16. Bollerslev J, Rosen T, Mollerup CL, Nordenström J, Baranowski M, Franco C, Pernow Y, Isaksen GA, Godang K, Ueland T, Jansson S; SIPH Study Group. Effect of sur-gery on cardiovascular risk factors in mild primary hyper-parathyroidism. J Clin Endocrinol Metab 2009;94:2255-61.
17. Cruickshank AM, Fraser WD, Burns HJ, Van Damme J, Shenkin A. Response of serum interleukin-6 in patients undergoing elective surgery of varying severity. Clin Sci (Lond) 1990;79:161-5. (Pubitemid 20218956)
18. Reppe S, Stilgren L, Abrahamsen B, Olstad OK, Cero F, Brixen K, Nissen-Meyer LS, Gautvik KM. Abnormal mus-cle and hematopoietic gene expression may be important for clinical morbidity in primary hyperparathyroidism. Am J Physiol Endocrinol Metab 2007;292:E1465-73. (Pubitemid 46684617)
19. Seeliger S, Hausberg M, Eue I, Usdin T, Rahn KH, Kosch M. The parathyroid hormone-2 receptor is expressed on human leukocytes and down-regulated in hyperparathyroidism. Clin Nephrol 2003;59:429-35. (Pubitemid 36722323)
20. Kotzmann H, Köller M, Abela C, Clodi M, Riedl M, Graninger W, Niederle B, Luger A. Effects of parathyroid hormone and serum calcium on the phenotype and function of mononuclear cells in patients with primary hyperparathy-roidism. Eur J Clin Invest 1998;28:353-8. (Pubitemid 28261217)
21. Ahmad S, Otaal PS, Rai TS, Bahl A, Saikia UN, Manoj RK, Thungapathra M, Talwar KK, Khullar M. Circulating proin-flammatory cytokines and N-terminal pro-brain natriuretic peptide significantly decrease with recovery of left ventricu-lar function in patients with dilated cardiomyopathy. Mol Cell Biochem 2009;324:139-45.
22. Bahrami H, Bluemke DA, Kronmal R, Bertoni AG, Lloyd-Jones DM, Shahar E, Szklo M, Lima JA. Novel metabolic risk factors for incident heart failure and their relationship with obesity: the MESA (Multi-Ethnic Study of Atheroscle-rosis) study. J Am Coll Cardiol 2008;51:1775-83. (Pubitemid 351608497)
23. Abdu TA, Elhadd T, Pfeifer M, Clayton RN. Endothelial dysfunction in endocrine disease. Trends Endocrinol Metab 2001;12:257-65. (Pubitemid 33714216)